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Abstract
Intellectual property enables the transformation of knowledge in principle and 
the link between knowledge and the market. The right of exclusivity guaranteed 
by the patent refers to the right to interfere with other products and use and sell a 
patented invention. On the other hand, access to the public is made available on the 
knowledge of the essential points and as those that characterize a novelty does not 
exist. Patent registries, because they are available in open access databases, are great 
bases of technological knowledge, which can be used in research in several areas, 
among them smoke inhalation treatments. Inhalation injury is the leading cause 
of death in burn patients and is usually caused by the uninhibited absorption of 
smoke, which has an extremely toxic effect on the respiratory system. The physio-
pathology of inhalation injury covers multiple factors, and the injured respiratory 
system may present deterioration in a few hours. Respiratory distress is one of the 
major causes of morbidity and mortality in patients affected by fire incidents. The 
search for suitable treatments for inhalation injury is continuing, and the treat-
ments used for smoke inhalation are discussed.
Keywords: patents, smoke inhalation, pulmonary injury, natural products,  
synthetic products
1. Introduction
A patent is a public concession, granted by the State, which grants the holder the 
exclusive right to commercially exploit his creation. The exclusivity right secured by 
the patent refers to the right to prevent others from manufacturing, using, selling, 
offering, or importing such invention. In compensation, access is available to the 
public on the knowledge of key points and the claims that characterize the novelty 
in the invention [1].
Patent registrations, because they are available in open access databases, are 
a great base of technological knowledge, which can be used in researches across 
several areas, among them smoke inhalation treatments [1].
The pulmonary injury from smoke inhalation or combustion chemical products 
is the leading cause of death in burn patients, can be present in 2/3 of the population 
Intellectual Property Rights - Patent
2
with skin burns exceeding 70% of body surface area, and is mainly caused by 
inhibited smoke inhalation, which has an extremely toxic effect in the respiratory 
system [2].
The physiopathology of an inhalation injury encompasses multiple factors, and 
the injured respiratory system can present deterioration in a few hours. If combined 
with cutaneous burns, the inhalation injury increases even more the incidence of 
pulmonary complications and the mortality. On average, the mortality from burns 
is less than 10%, but in the presence of an inhalation injury, this increases up to 
25–43%. When complications develop, such as pneumonia and multiple organ 
dysfunction, this can increase up to 60–80% [2].
The prevalence of burns is significantly higher in developing countries than in devel-
oped. In the USA, nearly 2 million people are burned every year. Of these, about 100,000 
have moderate to severe burns, requiring hospitalization, and 70% of fire victims who 
die within 12 h have an inhalation injury [3, 4]. In an epidemiological study conducted by 
Iqbal et al. [5], which evaluated 13,295 patients, it was found that men were the majority 
of the victims (56.43%); the mean age of adults was 33.63 ± 10.76 years and the children’s 
age was 6.71 ± 3.47 years, the domestic environment being the most common (68%). 
The mean body surface area burned was 10.64 ± 11.45% in total. Smoke inhalation injury 
occurred in 149 of these patients (1.12%).
Although many products and techniques have been developed to control cutane-
ous thermal injury, few specific therapeutical options for diagnosis were found for 
patients with inhalation injury. Several factors explain the slower improvement 
progress in the treatment of patients with inhalation injury. Inhalation injury is a 
more complex clinical problem. The burned cutaneous tissue can be removed and 
replaced by skin grafts. The injured pulmonary tissue must be protected from a 
secondary injury due to resuscitation, mechanical ventilation, and infection, while 
the host’s repair mechanisms receive proper support [2].
Many consequences of smoke inhalation result from an inflammatory response 
involving mediators whose number and functions still remain without a complete 
understanding, despite enhanced tools to process clinical material. Improvements 
in mortality by inhalation injury are mainly due widespread improvements in 
intensive care, instead of interventions focused in smoke inhalation. The search for 
proper inhalation treatments remains, and the treatments used for smoke inhala-
tion are discussed in this chapter.
2.  Intellectual property aimed at the treatment of pulmonary injury by 
smoke inhalation
Intellectual property enables a transformation of knowledge to principle and a 
link between knowledge and market. It is also said that a patent is the legal docu-
ment that represents the set of exclusivity rights granted by the State to an inventor. 
By receiving the patent rights over his product, the inventor also receives several 
rights and guarantees, however, with these rights also come obligations that, neces-
sarily, must be fulfilled so the inventor can retain his rights [1].
In case of him not meeting his obligations, he is subject to a mandatory licensing 
of his invention or utility model. If a patent is requested and granted for technol-
ogy, of a novelty product or to enhance an invention, there are several proceedings, 
regulations, and laws to register and grant these patents, which vary for each 
country, also varying the concession period. The delay in patent granting is pointed 
as a barrier to innovation in a country. According to the World Intellectual Property 
Organization (WIPO), the period for an international patent registration varies 
from 16 to 30 months [1].
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On patents deposited with the objective of treating injuries caused by smoke 
inhalation, the inventors that most developed e patented products were Enkhbaatar 
P. et al. (6), Keith JC Jr. (5), Schmalstieg F. et al. (1), Brands (5), and Saifer et al. (1).
3. Pulmonary injury and its therapeutical challenges
The constitution and toxicity of smoke and of products generated by combus-
tion compromise the environmental condition and health of exposed individuals, 
generating local or systemic affections, which may leave sequelae and even progress 
to death [2].
Inhalation injury by smoke can happen as a consequence of the high temperature 
of vapor inhaled, decrease of breathed fraction of oxygen, and presence of toxic 
gases such as carbon monoxide, sulfur dioxide, nitrogen, and ammonia, absorbed 
or not by the inhaled particulate matter [6, 7].
There are different damages to the different structures of the respiratory system 
[8]. In the airways, there is scaling of ciliated pseudostratified epithelium, mucosal 
edema, bronchorrhea, and tracheobronchial obstruction, increasing resistance and 
limiting air flow [9]. Sometimes, from the histological point of view, depending on 
the inhalation injury model, such changes can be reversible.
Regarding pulmonary parenchyma, the injuries are characterized by lung 
emphysema with expressive thinning of intra-alveolar septa, which burst and 
increase alveolar spaces. This tissue involvement can have progressive character, 
caused by the arrival of neutrophils in the pulmonary interstice, generating a 
superoxide radical, which directly harms the membrane of interstitial cells and the 
endothelium [10–12]. According to Ferreira and Matsubara [13], production and 
release of reactive oxygen species contribute to the emphysema.
About 6–7 h after initial exposure, there is an increase of IL-1β and IL-8 con-
centrations [14]. Besides those, other inflammatory process mediators are tumor 
necrosis factor-alpha (TNFɑ), IL-6, and nuclear factor-kappa β [2]. The actions of 
IL-1β, IL-6, and IL-8 stimulate adherence of leucocytes and disseminated intra-
vascular coagulation, with IL-6 highlighted in eosinophil attraction to the injured 
area [15]. TNF-ɑ is known for being a powerful inflammatory mediator in thermal 
lesions, inhalation injuries, and generalized infections [16].
Clinical treatment of an inhalation injury is a challenge based on the control of 
consequences of smoke exposure, there being no gold standard. Some immediate 
care assures the integrity of organs and systems of victims. It is necessary to start 
oxygen therapy with hyperoxia (FiO2 = 100%) for a limited time, to discern the 
indication of artificial airway and invasive or noninvasive ventilatory support, 
patient pronation, and extracorporeal membrane oxygenation [17].
It is important to maintain airway perversity as well as alveolar stability. The 
administration of β2-agonist, heparin and N-acetylcysteine nebulization have a role 
in the management, as well as the more specific treatment of carbon monoxide or 
cyanide poisoning, have contributed to good therapeutic results [18, 19].
Acknowledging the systemic effects of the condition, the hydration and 
monitoring of micro and macro hemodynamics are extremely relevant to prevent 
further complications. Pharmacological treatment is based on the consequences 
and additional complications. Corticosteroids, antibiotics, anticoagulants, seda-
tives, and analgesics and, in cases of intoxication by cyanide, hydroxocobalamin, 
sodium nitrite, sodium thiosulfate, or sodium nitrite, by intravenous route, can be 
administered [3, 20].
At the experimental level, the use of mesenchymal stem cells derived from 
human amnion (hAMSCs) alleviated white smoke-induced lung injury [21]. It is 
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likely that in the future this resource will contribute to the best clinical outcome for 
victims of this type of injury.
It is known, however, that the best clinical outcome for the victim of inhalation 
injury depends on other factors. According to Bedri et al. [22], socioeconomic and 
ethnic factors and the sex of the victims influence the clinical outcome. They found 
that Afro-descendent Americans, female and uninsured, had more complications, 
more surgical interventions, longer hospital stay, and higher mortality rates, even 
though lower body surface area burned and there is a lower proportion of inhaled 
lesion. These disparities further emphasize the need for further research on the 
underlying racial and socioeconomic factors that this review of the database could 
not discern.
In turn, natural products present great therapeutic potential and are the subject 
of study in several experimental, in vitro, and/or in vivo research. The low cost, the 
good availability, and the habitual use by the population, considering the regional 
popular knowledge, are some of the factors that contribute to this reality.
The terpene group deserves special mention, both for being part of traditional 
medicine for centuries and for having a low toxicity [23]. In addition to being used 
in the food and cosmetic industries, its effects, anti-inflammatories, antioxidants, 
analgesics, anticonvulsants, antidepressants, anxiolytics, anticancer, antitumor, 
neuroprotective, antimutagenic, antiallergic, antibiotics, and antidiabetics, are 
widely known.
Examples are carvacrol, linalool, borneol, limonene, myrene, and pinene. It is 
known, for example, that D-limonene has important immunomodulatory proper-
ties, ameliorating attacks of atopy and asthma, besides inhibiting the action of 
cytokines and release of substances reactive to oxygen and containing migration of 
eosinophils [2, 8].
4.  Historical background of patents aimed to control pulmonary injury 
by smoke inhalation
Two years ago, our research group performed a patent review [24] in three dif-
ferent databases, and only 18 patents, containing the keywords “smoke inhalation” 
in the title, abstract, or full text, fit in the inclusion criteria for this research. There 
was a language bias, making it possible for many other patents to exist, regarding 
the use of natural and synthetic products developed for the treatment of smoke 
inhalation, but we believe that the results presented provide the reader a perspec-
tive on current therapeutic options and new approaches and treatments for smoke 
inhalation.
The oldest patent was deposited in 1977 and was on “orgotein,” which is the 
generic name of the enzyme superoxide dismutase (SOD), which belongs to the 
metalloprotein group, contains copper and zinc, and was first described in 1969 by 
McCord and Fridovich. Those researchers found that a bovine protein (orgotein) 
was an enzyme that could catalyze the destruction of superoxide radicals through 
a disproportion in molecular oxygen and hydrogen peroxide. By destructing free 
superoxide radical, SOD contributes to the physiological balance between pro-
oxidants and antioxidants, being known for being a potent anti-inflammatory 
agent [24].
Dominguéz [25] reported that orgotein is a naturally occurring protein inside a 
human cell and, when topically and systematically administered, produces physi-
ological effects that do not manifest or manifest in a lower degree by the natural 
SOD of a patient. This exogenous manifestation decreases the amount of acute 
inflammatory events and influences late effects.
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The most recent patent, according to the patent review mentioned previously 
[24], was deposited in 2013 and was about ectophosphatases. The ectophosphatases 
and, especially, the alkaline phosphatases are a subclass of phosphatases (hydrolases 
that act on ester connections). The role of ectophosphatases is not well established 
yet; however, it has been suggested that these enzymes perform important tasks in 
nutrition, proliferation, differentiation, adhesion, virulence, and infection [26]. 
Furthermore, it is possible to assure that there is a consistent relation between the 
of an organism to decay extracellular ATP by ectophosphatases activities and its 
capacity to acquire resistance to toxins.
Brands [27] developed a drug using ectophosphatases for prophylaxis in mam-
mals, preferably humans, at risk of inflammatory diseases or immunocompromised 
conditions. Intravenous administration of alkaline phosphatase in patients sub-
jected to myocardial revascularization resulted in a subsequent increase in plasma 
levels of alkaline phosphatase 4–6 h after the onset of the surgery. This endogenous 
alkaline phosphatase can perform an important role in the immune system, because 
it acts as an acute phase protein; in addition, high levels of alkaline phosphatase 
generate an anti-inflammatory effect in the organism.
The two patented products mentioned previously, both the oldest and the new-
est, were applied and studied at the clinical level, in other words, with humans. The 
first product was given by inhalation (nebulization) and with a therapeutic purpose 
of treatment and the second, through intravenous infusion but with a preventive 
aspect [24].
The oldest patent found was deposited in a US-based patent database, yet the 
latest was located in Mexico. The year with most patent deposits related to the treat-
ment of inhalation injuries was 2009, followed by 2005 and 2008. Probably, that 
year had many researches and patent requests due to some disasters involving fires, 
such as the one in a club in Thailand, that resulted in many deceases [24].
5.  Patenting of processes and products aimed at pulmonary injury by 
smoke inhalation: any evidences?
Besides the two products mentioned and highlighted in the previous topic, since 
they were the first and the last to be patented, we had three other products studied 
and patented, e.g., “antithrombin III (ATIII) and heparin,” which refers to the exog-
enous administration of ATIII—a direct inhibitor of thrombin, and heparin, that 
inhibits coagulation proteases, decreasing fibrotic conditions and improving gas 
exchange in animal models of acute pulmonary injury. Since there were six patents 
deposited aimed at the use of this product, it was found that the inhaled admin-
istration (using a compressor nebulizer, an ultrasonic nebulizer, or a dry powder 
inhaler) is more efficient than intravenous injection [28]. The dose used was also 
mentioned in the patent, stressing that the inhalation of combined products can 
also be performed according to the need or symptom occurrence [29].
In five other patents, “estrogen receptor-β (ERβ)-selective ligands or composi-
tions,” with the objective of treating or preventing acute pulmonary injuries due 
to local inflammatory processes (smoke inhalation, prematurity with surfactant 
deficiency, oxygen toxicity, barotrauma by mechanical ventilation with positive 
pressure) or peritonitis or intravenous bacteremia, both during sepsis, were stud-
ied. Furthermore, many preclinical trials proved the anti-inflammatory properties 
of estrogen [29–31].
Finally, the patent on “anti-IL-8 and anti-L-selectin,” which we found only one 
patent deposited. L-selectin’s role in immunity control is as a receptor in T cells. The 
smoke inhalation model in sheep of Murakami and Traber [32] showed that the 
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anti-L-selectin antibody significantly alleviated airway obstruction. The neutrophil 
treatment with anti-L-selectin antibody reduces neutrophil capacity of adherence to 
the endothelium. It is also probable that chemokines such as IL-8 and others direct 
the neutrophil movement from the vasculature [33]. According to this patent, the 
effects on vascular permeability may point that both anti-IL-8 and anti-L-selectin 
decrease the lesions of endothelial cells.
These data help highlight the different means of treatment of injuries caused by 
smoke inhalation and the drugs being studied to control such injury. We presented 
the significant progress achieved in the field, demonstrating the growing interest 
of scholars and pharmaceutical companies in the development of products with the 
potential to be successful in treatment of smoke inhalation.
6.  The challenges of processes and patents aimed at pulmonary injury by 
smoke inhalation
Intellectual property, one of the subdivisions of business law, is nothing more 
than the legislative norm that regulates innovations and is now gaining consider-
able space in the most varied academic discussions. Patent, one of the intellectual 
property entities, is the guarantee of ownership of the creation offered to its 
inventors, a fact that has been discussed since it ends up limiting its application and 
effectiveness [34].
The expression of intellectual property is criticized because of its ambigu-
ity. Richard Stallman wrote an essay on this subject to enlighten this problem 
and fight, among other things, against other things, against the meaning of the 
expression, because it is a reminiscence of physical property, whose laws are very 
different. For him, the term unites a set of heterogeneous concepts with objectives 
and operation too diverging (or even opposed) to be considered as a whole, such 
as copyrights, related to patents and trademarks. He advocates a separate consider-
ation of each of these areas and the abandonment of the term intellectual property 
(especially in the name of the World Intellectual Property Organization) [1, 34]. 
Actually, part of the free software community rejects this expression and follows 
Stallman’s point of view.
As previously explained, patenting a product guarantees its inventor time to 
explore its invention safely, but there are a number of limitations in this action [35, 
36]. One of the biggest challenges in the patent process in some countries is the 
delay in the patenting process and the low investment in this area, which does not 
generate incentives for research, studies, and creations of new products. The cost 
of a patent goes beyond the process to deposit it into a database; there is still a high 
investment to keep it active, which discourages some inventors who have low invest-
ment in their research.
Once a patent is deposited in a database, the entire population has access to 
the methodology of the invention as well as its advantages and disadvantages. 
Analyzing database patents, besides the analysis in the literature, is an important 
tool in the strategic planning of a research, because approximately 70% of the tech-
nological information is described in the patents, according to WIPO. Therefore, a 
thorough evaluation of patents is essential for a good development of projects and 
avoids potential wasted resources, in case any other researcher has already reached 
the expected goal.
Currently, there are several databases for patent deposits. These banks are 
extremely affordable and consistent, but they have some limitations. A great 
difficulty encountered is the duplication of patents during a search, which occurs 
because the same inventor ends up depositing his patent in several databases. In 
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the reviews of patents carried out by our group, we find a considerable number of 
patents in duplicity, which makes the research more laborious and time-consuming. 
In addition, some inventors are rather short, brief, and unspecific when carrying 
out the explanation of their patent. At other times, they are prolix and not objective, 
which end up generating difficulties in the process of searching and analyzing the 
most desired patents.
Another limitation is the difficulty of finding a specific patent. Due to various 
encodings and numberings given to patents, the search for something specific ends 
up taking more time. The lack of research in clinical trials is, also, another limiting 
factor. Most inventors carry out the patent filing process with an experimental trial, 
which can be justified by the interest of patenting their invention more quickly and 
not running the risk of another inventor developing their research. In the patent 
review conducted by our research group on inhalation injury 2 years ago, only three 
patents were found in clinical trials.
Regarding patents aimed at treatment for lung injury induced by smoke inhala-
tion, specifically, we can observe an increasing amount of deposits in the last years. 
However, morbidity and mortality remain high, probably due to its extremely 
complicated pathophysiology. Besides the damages of the toxic and harmful gas, the 
oxidative stress, the interaction between cytokines and inflammatory mediators, 
and the activation of the NF-κB signaling pathway contribute to a greater difficulty 
in the treatment and control of this condition, making it difficult to standardize the 
research of new patents for strategies of treatment [9].
In the patent review conducted by our research group, which aimed to evaluate 
the development and patenting of natural and synthetic products for the treat-
ment of smoke inhalation, a low number of patents deposited (18 in total) can be 
observed for this purpose. In addition, a great variety of both the mechanisms of 
action of the formulations and the form of administration of the formulations were 
observed [24]. Most new therapies are still at the stage of animal experimentation.
Early treatment remains the key to reducing mortality and improving prognosis. 
The inconsistent effects of certain therapies may be due to the diverse dose, mecha-
nism of action, therapeutic duration, severity of the patients, and complementary 
interventions [37].
7. Conclusion
Developing better treatment strategies for this intractable disease still requires 
research, and the intellectual property enables the transformation of knowledge 
in principle and the link between knowledge and the market. However, currently, 
there is no particularly effective treatment for acute lung injury induced by inhala-
tion of smoke; therefore, the search for suitable treatments for inhalation injury is 
continuing, and the treatments used for smoke inhalation are discussed.
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